NO321377B1 - Nye forbindelser - Google Patents

Nye forbindelser Download PDF

Info

Publication number
NO321377B1
NO321377B1 NO20015383A NO20015383A NO321377B1 NO 321377 B1 NO321377 B1 NO 321377B1 NO 20015383 A NO20015383 A NO 20015383A NO 20015383 A NO20015383 A NO 20015383A NO 321377 B1 NO321377 B1 NO 321377B1
Authority
NO
Norway
Prior art keywords
tert
mmol
pyridin
amino
added
Prior art date
Application number
NO20015383A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015383L (no
NO20015383D0 (no
Inventor
Marcel Linschoten
Magnus Polla
Peder Svensson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20015383D0 publication Critical patent/NO20015383D0/no
Publication of NO20015383L publication Critical patent/NO20015383L/no
Publication of NO321377B1 publication Critical patent/NO321377B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
NO20015383A 1999-05-03 2001-11-02 Nye forbindelser NO321377B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9901573A SE9901573D0 (sv) 1999-05-03 1999-05-03 New compounds
PCT/SE2000/000834 WO2000066557A1 (fr) 1999-05-03 2000-05-03 Nouveaux composes

Publications (3)

Publication Number Publication Date
NO20015383D0 NO20015383D0 (no) 2001-11-02
NO20015383L NO20015383L (no) 2001-12-21
NO321377B1 true NO321377B1 (no) 2006-05-02

Family

ID=20415426

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015383A NO321377B1 (no) 1999-05-03 2001-11-02 Nye forbindelser

Country Status (27)

Country Link
US (1) US7071175B1 (fr)
EP (1) EP1180098A1 (fr)
JP (1) JP2002543184A (fr)
KR (1) KR100755152B1 (fr)
CN (1) CN1263739C (fr)
AR (1) AR034241A1 (fr)
AU (1) AU771760B2 (fr)
BR (1) BR0010257A (fr)
CA (1) CA2371213C (fr)
CZ (1) CZ20013930A3 (fr)
EE (1) EE04490B1 (fr)
HK (1) HK1042303A1 (fr)
HU (1) HUP0202876A3 (fr)
IL (1) IL145954A0 (fr)
IS (1) IS6139A (fr)
MX (1) MXPA01011055A (fr)
MY (1) MY128014A (fr)
NO (1) NO321377B1 (fr)
NZ (1) NZ515062A (fr)
PL (1) PL200932B1 (fr)
RU (1) RU2244708C2 (fr)
SE (1) SE9901573D0 (fr)
SK (1) SK15462001A3 (fr)
TR (1) TR200103153T2 (fr)
TW (1) TWI232105B (fr)
WO (1) WO2000066557A1 (fr)
ZA (1) ZA200108968B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828566B2 (en) * 1997-07-22 2004-12-07 Hitachi Ltd Method and apparatus for specimen fabrication
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
US6576627B1 (en) 1999-09-14 2003-06-10 Meiji Seika Kaisha Ltd. Phosphonic acid derivatives having carboxypeptidase b inhibitory activity
US7214831B2 (en) 2002-05-22 2007-05-08 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-chalcogenmethylcarbonyl compounds
SE0103272D0 (sv) 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
US6713496B2 (en) 2002-01-22 2004-03-30 Pfizer Inc 3-(imidazolyl)-2-alkoxypropanoic acids
BR0307033A (pt) 2002-01-22 2004-12-07 Pfizer ácidos 3-(imidazolil)-2-aminopropanóicos para o uso como inibidores tafi-a para o tratamento de doenças trombóticas
US7528173B2 (en) * 2002-03-21 2009-05-05 Schering Aktiengesellshaft Plasma carboxypeptidase B inhibitors
SE0201837D0 (sv) * 2002-06-14 2002-06-14 Astrazeneca Ab Chemical compounds
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
AU2009290474A1 (en) 2008-09-11 2010-03-18 Pfizer Inc. Heteroaryls amide derivatives and their use as glucokinase activators
WO2010050525A1 (fr) 2008-10-29 2010-05-06 大正製薬株式会社 Composé ayant une activité inhibitrice des tafia
EP2389374A1 (fr) 2009-01-20 2011-11-30 Pfizer Inc. Pyrazinone amides substitués
EP2604604A1 (fr) 2009-03-11 2013-06-19 Pfizer Inc Dérivés de benzofuranyle utilisés comme inhibiteurs de la glucokinase
AU2010341530B2 (en) 2009-12-22 2016-03-10 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
CN102249992A (zh) * 2011-07-05 2011-11-23 广东工业大学 一种制备2-氨基异烟酸的方法
CA2856196C (fr) 2011-12-06 2020-09-01 Masco Corporation Of Indiana Distribution d'ozone dans un robinet
KR20160018557A (ko) 2013-06-10 2016-02-17 사노피 TAFIa의 저해제로서의 마크로사이클릭 우레아 유도체, 이의 제법 및 의약품으로서의 이의 용도
AR099134A1 (es) * 2014-01-24 2016-06-29 Hoffmann La Roche Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina
WO2017112795A1 (fr) 2015-12-21 2017-06-29 Delta Faucet Company Système de distribution de fluide comprenant un dispositif désinfectant
USD879309S1 (en) 2018-08-09 2020-03-24 Scott Specialties, Inc. Maternity support

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091569A (en) 1960-08-26 1963-05-28 Mead Johnson & Co Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus
FR1393338A (fr) 1964-01-08 1965-03-26 Rech S Pharma Et Scient Nouveau dérivé de la cystéine et sa préparation
US3766206A (en) 1971-11-03 1973-10-16 Pfizer 18beta-glycyrrheting acid amides useful as antiulcer agents
FR2266502A1 (en) 1974-04-08 1975-10-31 Synpharm Sa N-(2-thenoyl)-cysteine and esters - with mucolytic activity, prepd. from cysteine (esters) and thenoyl chloride
US4177277A (en) 1977-01-17 1979-12-04 E. R. Squibb & Sons, Inc. Method for alleviating hypertension
US4113715A (en) 1977-01-17 1978-09-12 E. R. Squibb & Sons, Inc. Amino acid derivatives
JPS545949A (en) 1977-06-16 1979-01-17 Hisamitsu Pharmaceut Co Inc Novel cyclohexanecarboxylic acid and its derivatives
FR2430945A2 (fr) 1978-07-12 1980-02-08 Chauvin Blache Lab Nouveaux derives de la cysteine, leur procede de fabrication et leur application en therapeutique
US4537727A (en) 1982-11-12 1985-08-27 Eli Lilly And Company Process for recovering 2-acetylthiomethyl-5-aminopentanoic acid
EP0136883B1 (fr) * 1983-10-03 1987-11-25 E.R. Squibb & Sons, Inc. Inhibiteurs d'enképhalinase
WO1986004580A1 (fr) * 1985-02-08 1986-08-14 Takeda Chemical Industries, Ltd. Derives de piperidine
US4708965A (en) 1985-09-16 1987-11-24 Morgan Lee R Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives
JPS62270555A (ja) * 1986-05-19 1987-11-24 Dainippon Pharmaceut Co Ltd スルホン酸誘導体およびその塩
EP0318859A3 (fr) 1987-12-03 1990-08-16 Dainippon Pharmaceutical Co., Ltd. Dérivés N-substitués de mercaptopropionamide
JPH01254654A (ja) * 1988-04-01 1989-10-11 Dainippon Pharmaceut Co Ltd スルホン酸の誘導体及びその塩
EP0361365A1 (fr) 1988-09-30 1990-04-04 E.R. SQUIBB & SONS, INC. Composés d'acides aminobenzoiques et aminocyclohexane carboxyliques, compositions, et méthode d'application
DE3838467C2 (de) 1988-11-12 1998-12-10 Agfa Gevaert Ag Fotografisches Aufzeichnungsmaterial
CA2038066A1 (fr) 1990-08-09 1992-02-10 Hiroshi Fukumi Derives de l'acide (benzhydryloxyethylpiperidyl)aliphatique et leur utilisation dans le traitement des allergies et de l'asthme
IT1249650B (it) 1991-05-29 1995-03-09 Poli Ind Chimica Spa N-(5-tioxo-l-prolil)-l-cisteina e suoi derivati, loro preparazione ed impiego terapeutico
GB9122016D0 (en) 1991-10-16 1991-11-27 Glaxo Group Ltd Chemical compounds
IT1266571B1 (it) * 1993-07-30 1997-01-09 Zambon Spa Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari
US5470834A (en) * 1993-10-06 1995-11-28 Florida State University Sulfoximine and suldodiimine matrix metalloproteinase inhibitors
DE4441873A1 (de) * 1994-11-24 1996-05-30 Wella Ag Mittel zur dauerhaften Haarverformung
JP3874455B2 (ja) * 1996-06-27 2007-01-31 新日本製鐵株式会社 フィブリノーゲン受容体拮抗物質およびそれを有効成分とする医薬製剤

Also Published As

Publication number Publication date
AR034241A1 (es) 2004-02-18
HK1042303A1 (zh) 2002-08-09
AU771760B2 (en) 2004-04-01
CA2371213C (fr) 2009-11-10
PL354360A1 (en) 2004-01-12
SK15462001A3 (sk) 2002-11-06
IS6139A (is) 2001-11-01
NO20015383L (no) 2001-12-21
NZ515062A (en) 2004-04-30
TWI232105B (en) 2005-05-11
KR20020010630A (ko) 2002-02-04
EE04490B1 (et) 2005-06-15
JP2002543184A (ja) 2002-12-17
HUP0202876A2 (hu) 2003-01-28
EP1180098A1 (fr) 2002-02-20
WO2000066557A1 (fr) 2000-11-09
TR200103153T2 (tr) 2002-04-22
CA2371213A1 (fr) 2000-11-09
PL200932B1 (pl) 2009-02-27
AU4790200A (en) 2000-11-17
SE9901573D0 (sv) 1999-05-03
KR100755152B1 (ko) 2007-09-04
CN1263739C (zh) 2006-07-12
RU2244708C2 (ru) 2005-01-20
IL145954A0 (en) 2002-11-10
BR0010257A (pt) 2002-02-13
ZA200108968B (en) 2003-09-05
CZ20013930A3 (cs) 2002-10-16
MXPA01011055A (es) 2002-06-04
US7071175B1 (en) 2006-07-04
EE200100574A (et) 2003-02-17
CN1358174A (zh) 2002-07-10
MY128014A (en) 2007-01-31
HUP0202876A3 (en) 2005-07-28
NO20015383D0 (no) 2001-11-02

Similar Documents

Publication Publication Date Title
NO321377B1 (no) Nye forbindelser
IL123986A (en) Medicinal compounds
SK172098A3 (en) New amidino derivatives and their use as thrombin inhibitors
IL149042A (en) Non-covalent inhibitors of urokinase and vascular formation
US20090012087A1 (en) New Aza-Bicyclohexane Compounds Useful As Inhibitors Of Thrombin
US20220298138A1 (en) Enzyme inhibitors
NO317135B1 (no) Nye aminosyrederivater, farmasoytisk formulering inneholdende slike derivater, fremgangsmate for og deres fremstilling, og deres anvendelse som trombininhibitorer
NO317096B1 (no) Nye forbindelser, farmasoytisk formulering inneholdende slike forbindelser, fremgangsmate for deres fremstilling, og anvendelse derav
NZ515026A (en) Heterocyclic amidine derivatives useful as prodrugs of thrombin inhibitors
US7423012B2 (en) Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors
EP2204373A1 (fr) Dérivés de l'acid phosphonic comme inhibiteurs de Plasma Carboxypeptidase B
CZ20032101A3 (cs) Peptidové sloučeniny
JP3700854B2 (ja) 線維化抑制剤
US20080200431A1 (en) Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa
EP1526131A1 (fr) Aminoalkyl-pyrazinones et -pyridones et leur utilisation comme inhibiteurs de la thrombine
JPH10306092A (ja) ２−ピペラジノン−１−酢酸誘導体及びその用途
CZ20002070A3 (cs) Nové sloučeniny

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees